Berkshire Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.41M | Sell |
3,152
-227
| -7% | -$106K | 0.06% | 119 |
|
|
2025
Q4 | $1.53M | Buy |
3,379
+9
| +0.3% | +$3.88K | 0.07% | 117 |
|
|
2025
Q3 | $1.32M | Hold |
3,370
| – | – | 0.06% | 136 |
|
|
2025
Q2 | $1.5M | Hold |
3,370
| – | – | 0.07% | 124 |
|
|
2025
Q1 | $1.45M | Sell |
3,370
-274
| -8% | -$128K | 0.07% | 123 |
|
|
2024
Q4 | $1.6M | Sell |
3,644
-759
| -17% | -$352K | 0.08% | 122 |
|
|
2024
Q3 | $2.06M | Hold |
4,403
| – | – | 0.11% | 98 |
|
|
2024
Q2 | $2.06M | Sell |
4,403
-386
| -8% | -$168K | 0.1% | 99 |
|
|
2024
Q1 | $2M | Sell |
4,789
-77
| -2% | -$32.6K | 0.11% | 89 |
|
|
2023
Q4 | $1.98M | Sell |
4,866
-23
| -0.5% | -$8.5K | 0.11% | 86 |
|
|
2023
Q3 | $1.7M | Sell |
4,889
-49
| -1% | -$17.1K | 0.11% | 92 |
|
|
2023
Q2 | $1.74M | Buy |
4,938
+125
| +3% | +$42.1K | 0.1% | 92 |
|
|
2023
Q1 | $1.52M | Buy |
+4,813
| New | +$1.44M | 0.09% | 94 |
|
|
2022
Q4 | – | Sell |
-4,969
| Closed | -$1.44M | – | 214 |
|
|
2022
Q3 | $1.44M | Sell |
4,969
-1,162
| -19% | -$334K | 0.1% | 87 |
|
|
2022
Q2 | $1.73M | Sell |
6,131
-1,119
| -15% | -$300K | 0.11% | 84 |
|
|
2022
Q1 | $1.89M | Sell |
7,250
-2,732
| -27% | -$648K | 0.12% | 78 |
|
|
2021
Q4 | $2.19M | Sell |
9,982
-205
| -2% | -$39.9K | 0.13% | 81 |
|
|
2021
Q3 | $1.85M | Sell |
10,187
-65
| -0.6% | -$12.7K | 0.12% | 88 |
|
|
2021
Q2 | $2.07M | Sell |
10,252
-1,186
| -10% | -$248K | 0.14% | 82 |
|
|
2021
Q1 | $2.46M | Buy |
11,438
+4,129
| +56% | +$907K | 0.18% | 70 |
|
|
2020
Q4 | $1.73M | Buy |
7,309
+4,538
| +164% | +$1.04M | 0.13% | 82 |
|
|
2020
Q3 | $754K | Buy |
2,771
+360
| +15% | +$99.3K | 0.07% | 98 |
|
|
2020
Q2 | $700K | Sell |
2,411
-2,665
| -53% | -$723K | 0.06% | 100 |
|
|
2020
Q1 | $1.21M | Buy |
5,076
+3,311
| +188% | +$760K | 0.13% | 91 |
|
|
2019
Q4 | $386K | Sell |
1,765
-49
| -3% | -$9.92K | 0.03% | 138 |
|
|
2019
Q3 | $307K | Hold |
1,814
| – | – | 0.03% | 174 |
|
|
2019
Q2 | $333K | Buy |
1,814
+351
| +24% | +$61.4K | 0.03% | 168 |
|
|
2019
Q1 | $269K | Hold |
1,463
| – | – | 0.02% | 194 |
|
|
2018
Q4 | $242K | Sell |
1,463
-400
| -21% | -$69.3K | 0.02% | 192 |
|
|
2018
Q3 | $359K | Hold |
1,863
| – | – | 0.03% | 174 |
|
|
2018
Q2 | $317K | Hold |
1,863
| – | – | 0.03% | 170 |
|
|
2018
Q1 | $304K | Hold |
1,863
| – | – | 0.03% | 171 |
|
|
2017
Q4 | $279K | Sell |
1,863
-26
| -1% | -$3.85K | 0.03% | 176 |
|
|
2017
Q3 | $287K | Buy |
1,889
+26
| +1% | +$3.91K | 0.03% | 160 |
|
|
2017
Q2 | $240K | Sell |
1,863
-269
| -13% | -$32.4K | 0.03% | 178 |
|
|
2017
Q1 | $233K | Buy |
+2,132
| New | +$188K | 0.03% | 178 |
|
|
2016
Q1 | – | Sell |
-1,713
| Closed | -$216K | – | 168 |
|
|
2015
Q4 | $216K | Buy |
+1,713
| New | +$207K | 0.04% | 146 |
|
|
2015
Q3 | – | Sell |
-1,813
| Closed | -$224K | – | 161 |
|
|
2015
Q2 | $224K | Hold |
1,813
| – | – | 0.04% | 149 |
|
|
2015
Q1 | $214K | Sell |
1,813
-671
| -27% | -$80.4K | 0.04% | 155 |
|
|
2014
Q4 | $295K | Hold |
2,484
| – | – | 0.05% | 139 |
|
|
2014
Q3 | $279K | Hold |
2,484
| – | – | 0.05% | 141 |
|
|
2014
Q2 | $235K | Buy |
+2,484
| New | +$174K | 0.04% | 152 |
|
Other funds holding VRTX
VCM
VPM
Berkshire Asset Management's VRTX Position: Q1 2026 in Review
Berkshire Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 6.7% in Q1 2026, selling an estimated $106K and leaving 3,152 shares worth $1.41M. The position accounts for 0.06% of the portfolio, ranked #119.
Berkshire Asset Management first reported a position in VRTX in Q2 2014 and has held it in 42 quarters since. The position peaked at $2.46M in Q1 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Berkshire Asset Management held 3,152 shares of Vertex Pharmaceuticals worth $1.41M as of Q1 2026.
- Berkshire Asset Management sold 227 Vertex Pharmaceuticals shares in Q1 2026, an estimated $106K.
- Vertex Pharmaceuticals made up 0.06% of Berkshire Asset Management's portfolio in Q1 2026, its #119 holding.
- Berkshire Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 42 quarters since.
- Berkshire Asset Management's Vertex Pharmaceuticals position peaked at $2.46M in Q1 2021.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Berkshire Asset Management's 13F filing for Q1 2026, filed 11 May 2026.